Cannabis Science Proposes New Trans-Dermal Patches for Patients with Fibromyalgia and Acute Diabetic Neuropathy
Cannabis science a company specializing in the development of therapeutic cannabis, has recently announced the development of two new drugs to relieve pain in people with fibromyalgia and acute diabetic neuropathy. These two new pharmaceutical analgesics will be marketed as transdermal patches. These deliver a certain amount of CBD or THC into the bloodstream through absorption through the patient's skin.
Pain of Acute Diabetic Neuropathy & Fibromyalgia
Acute diabetic neuropathy is a complication of diabetes. It is a very common disease in people with diabetes who have been living for many years. And its occurrence is even earlier than the diabetes is poorly balanced.
Diabetic neuropathy manifests itself differently from one case to another depending on whether the autonomic nervous system, motor or sensory, is affected. In addition, these sensitivity disorders that can lead to disasters. Including amputation of the lower limbs in the case of a loss of "acute" sensibility in the feet. But more generally, they are intense (burning) sensations. These disorders are responsible for gait disorders and can sometimes reach the crural nerve with pain and loss of sensitivity, particularly in the thigh.
Patients with fibromyalgia suffer from chronic pain similar to the ills of acute diabetic neuropathy. In the case of these pains only, this new treatment is exercised by the transdermal administration routes. Indeed, these pathways have the potential to promote the healing of an injured area of the body.
The patch provides a more controlled release of the drug, either by using a porous membrane to allow the drug to be gradually absorbed through the skin, or by incorporating thin layers of the drug into the adhesive that melts with heat of the patient's body.
These patches will contain a high-activity cannabinoid extract (CBD), the second major cannabinoid of marijuana. And others will contain THC (tetrahydrocannabinol). The extract slowly enters the bloodstream and then into the central nervous system of a patient to act as an analgesic.
"As more and more states at the national level [in the US] legislate for the legalization of cannabis and cannabis-based drugs, here at Cannabis Science, we focus on the development of pharmaceutical formulations to meet the huge growing demand expected over the next few years "The director of Cannabis Science.
Fibromyalgia is estimated to affect 2% -8% of the population. Thus this delivery method may be superior to other types of drug, including oral, topical, intravenous, intramuscular, and the like, because of the additional control over the dose administered to the patient.